Volume 131, Issue 3, Pages (November 2007)

Slides:



Advertisements
Similar presentations
The Small-Molecule Iron Transport Inhibitor Ferristatin/NSC Promotes Degradation of the Transferrin Receptor  Lior Horonchik, Marianne Wessling-Resnick 
Advertisements

Volume 50, Issue 6, Pages (June 2013)
Volume 36, Issue 5, Pages (December 2009)
Volume 41, Issue 5, Pages (March 2011)
Volume 129, Issue 6, Pages (June 2007)
Chaperone Activity with a Redox Switch
Phosphorylation of Cdc20 by Bub1 Provides a Catalytic Mechanism for APC/C Inhibition by the Spindle Checkpoint  Zhanyun Tang, Hongjun Shu, Dilhan Oncel,
Volume 37, Issue 5, Pages (March 2010)
Activating and Silencing the Mitotic Checkpoint through CENP-E-Dependent Activation/Inactivation of BubR1  Yinghui Mao, Ariane Abrieu, Don W. Cleveland 
Chaperone Activity with a Redox Switch
Volume 4, Issue 3, Pages (August 2013)
Monica C. Rodrigo-Brenni, Erik Gutierrez, Ramanujan S. Hegde 
J. Winter, M. Ilbert, P.C.F. Graf, D. Özcelik, U. Jakob  Cell 
Volume 47, Issue 1, Pages (July 2012)
The Nogo Receptor NgR1 Mediates Infection by Mammalian Reovirus
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Volume 40, Issue 1, Pages (October 2010)
Volume 97, Issue 2, Pages (July 2009)
Volume 40, Issue 6, Pages (December 2010)
Volume 24, Issue 10, Pages (October 2016)
SV40 VP2 and VP3 Insertion into ER Membranes Is Controlled by the Capsid Protein VP1: Implications for DNA Translocation out of the ER  Robert Daniels,
Volume 20, Issue 2, Pages (October 2005)
Wendy F. Ochoa, Anju Chatterji, Tianwei Lin, John E. Johnson 
Jeremy S. Paige, Guoqiang Xu, Branka Stancevic, Samie R. Jaffrey 
Zhonglin Mou, Weihua Fan, Xinnian Dong  Cell 
SUMO-2 Orchestrates Chromatin Modifiers in Response to DNA Damage
Volume 134, Issue 5, Pages (September 2008)
Volume 20, Issue 4, Pages (April 2011)
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Volume 38, Issue 5, Pages (June 2010)
Volume 66, Issue 4, Pages e5 (May 2017)
Volume 70, Issue 2, Pages e6 (April 2018)
Volume 20, Issue 14, Pages (July 2010)
Inactivation of the SMN Complex by Oxidative Stress
Volume 137, Issue 1, Pages (April 2009)
Chemical Dissection of an Essential Redox Switch in Yeast
Volume 13, Issue 1, Pages (January 2004)
Real-Time Redox Measurements during Endoplasmic Reticulum Stress Reveal Interlinked Protein Folding Functions  Philip I. Merksamer, Ala Trusina, Feroz.
SUMO-2 Orchestrates Chromatin Modifiers in Response to DNA Damage
c-Src Activates Endonuclease-Mediated mRNA Decay
Sichen Shao, Ramanujan S. Hegde  Molecular Cell 
Calnexin Discriminates between Protein Conformational States and Functions as a Molecular Chaperone In Vitro  Yoshito Ihara, Myrna F Cohen-Doyle, Yoshiro.
Protein Translocation Is Mediated by Oligomers of the SecY Complex with One SecY Copy Forming the Channel  Andrew R. Osborne, Tom A. Rapoport  Cell  Volume.
Volume 96, Issue 3, Pages (February 1999)
Volume 121, Issue 4, Pages (May 2005)
Volume 39, Issue 2, Pages (July 2010)
Virus-Induced Abl and Fyn Kinase Signals Permit Coxsackievirus Entry through Epithelial Tight Junctions  Carolyn B. Coyne, Jeffrey M. Bergelson  Cell 
Polypyrimidine Tract Binding Protein Blocks the 5′ Splice Site-Dependent Assembly of U2AF and the Prespliceosomal E Complex  Shalini Sharma, Arnold M.
Guillaume Bossis, Frauke Melchior  Molecular Cell 
Cellular 5′-3′ mRNA Exonuclease Xrn1 Controls Double-Stranded RNA Accumulation and Anti-Viral Responses  Hannah M. Burgess, Ian Mohr  Cell Host & Microbe 
Richard W. Deibler, Marc W. Kirschner  Molecular Cell 
Volume 127, Issue 2, Pages (October 2006)
The Prolyl Isomerase Pin1 Functions in Mitotic Chromosome Condensation
Detecting Folding Intermediates of a Protein as It Passes through the Bacterial Translocation Channel  Hiroshi Kadokura, Jon Beckwith  Cell  Volume 138,
Volume 4, Issue 3, Pages (August 2013)
Volume 13, Issue 10, Pages (December 2015)
Volume 49, Issue 6, Pages (March 2013)
Volume 37, Issue 4, Pages (February 2010)
Volume 9, Issue 5, Pages (May 2001)
USP15 Negatively Regulates Nrf2 through Deubiquitination of Keap1
Volume 27, Issue 6, Pages e4 (May 2019)
Volume 39, Issue 2, Pages (July 2010)
Jeremy S. Paige, Guoqiang Xu, Branka Stancevic, Samie R. Jaffrey 
Volume 7, Issue 6, Pages (June 2001)
Yuki Okuda-Shimizu, Linda M. Hendershot  Molecular Cell 
Tatiana Soldà, Carmela Galli, Randal J. Kaufman, Maurizio Molinari 
Volume 65, Issue 5, Pages e4 (March 2017)
AppA Is a Blue Light Photoreceptor that Antirepresses Photosynthesis Gene Expression in Rhodobacter sphaeroides  Shinji Masuda, Carl E. Bauer  Cell  Volume.
James H. Cormier, Taku Tamura, Johan C. Sunryd, Daniel N. Hebert 
Yun-Gui Yang, Tomas Lindahl, Deborah E. Barnes  Cell 
Presentation transcript:

Volume 131, Issue 3, Pages 516-529 (November 2007) Simian Virus 40 Depends on ER Protein Folding and Quality Control Factors for Entry into Host Cells  Mario Schelhaas, Johan Malmström, Lucas Pelkmans, Johannes Haugstetter, Lars Ellgaard, Kay Grünewald, Ari Helenius  Cell  Volume 131, Issue 3, Pages 516-529 (November 2007) DOI: 10.1016/j.cell.2007.09.038 Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 1 ER Processes and ER Proteins Are Associated with SV40 Infection CV-1 (A–C) or HeLa (D) cells were infected with SV40 (one plaque-forming unit (PFU)/cell). The data represent the average ± SD of three independent experiments. (A) Pharmacological inhibitors were added 30 min prior to addition of virus and present during infection (100 μM kifunensine, 5 μM castanospermine, 20 μM MG-132, 5 μM omuralide, 2 μM geldanamycin, 1 μM thapsigargin, and 5 mM DTT). (B) As in (A). Inhibitors were present either throughout infection (black), or added at 8 hr p.i. (white). (C) 5 mM DTT was added at given times postaddition of SV40 (solid line). Alternatively, cells were infected in the presence of 5 μM nocodazole (noc). At 2 hr p.i, noc was washed out, and 5 mM DTT was added (dashed line). DTT inhibition was similar with or without noc, a microtubule-dissociating agent that allows virus uptake into caveosomes but prevents further transport to the ER (Pelkmans et al., 2001), and thus confirmed that the DTT sensitive step occurred after exit from the caveosome. (D) siRNA silencing was achieved by transfection of siRNAs (Figure S1). A margin for insignificant pertubations of infection (±20%) was indicated by dashed lines. Cell 2007 131, 516-529DOI: (10.1016/j.cell.2007.09.038) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 2 Free Sulfhydryls in SV40 Are Critical during Entry CV-1 cells were infected with SV40 (1 PFU/cell [A]; 10 PFU/cell [B]). The data represent the average ± SD of three independent experiments. (A) SV40 was thiol-disulfide modified by reduction (5 mM DTT), oxidation (5 mM diamide), or alkylation (5 mM AMS or IAA) prior to addition to cells. (B) Cells were infected with AF488 labeled SV40 in the absence or presence of 5 mM DTT. Alternatively, alkylated AF488 labeled SV40 (5 mM AMS) was added. Cells were fixed at 2 or 8 hr p.i., and immunostained for caveolin-1 or PDI, respectively. After confocal image aquisition, the amount of colocalization of SV40 (green) with cellular markers (red) was quantified and normalized to SV40 in the absence of DTT. Cell 2007 131, 516-529DOI: (10.1016/j.cell.2007.09.038) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 3 Characterization of SV40 Cysteines in Intact Virions (A) Intact SV40 particles were alkylated by malPEG, followed by DTT reduction and alkylation of all remaining cysteines by IAA in the presence of SDS (lane 2). Alternatively, SV40 was reduced in the presence of SDS and alkylated with IAA (lane 1) or with malPEG/IAA mixtures (as indicated). The latter identified band shifts conferred by single or multiple (up to four) malPEG modifications (lanes 3 and 4) Numbers indicate the order of addition of the reagents. (B) Outline for the identification of the individual SV40 cysteines present as free sulfhydryls or disulfide bonded by mass spectrometry. Strategy 1 labeled reduced and exposed cysteines differently than all other cysteines by alkylation with IAM of intact SV40. All further cysteines were alkylated by MMTS, after DTT reduction and SDS-denaturation. Strategy 2 labeled the reduced and exposed as well as the disulfide bonded cysteines differently than the reduced and hidden species (gray) by DTT reduction followed by IAM alkylation. IAM was quenched with DTT, and hidden cysteines were alkylated by MMTS in the presence of SDS. Samples were submitted to SDS-PAGE and Coomassie staining. VP1 was excised and subjected to an in-gel trypsin digest; peptides were eluted and analyzed by mass spectrometry. The mass difference for IAM and MMTS was used to distinguish individual cysteines. (C) Summary of the thiol-modifications of VP1 cystein residues detected by mass spectrometry (see also Figure S3 and Tables S1 and S2). (D) Ribbon diagram of a single VP1 molecule as present in a pentamer. Highlighted in red are the cysteine residues. Dashed lines indicate reduced and exposed cysteines; solid lines indicate disulfide bonded cysteines. (E) Nonreducing SDS-PAGE and Coomassie staining of purified SV40 after treatment with SDS, DTT (lane 1), or after subsequent treatment with DTT, IAM, and SDS (lane 2), with IAM and SDS (lane 3), or with IAM, DTT, and SDS (lane 4). Numbers indicate the order of addition of reagents. All disulfides could be reduced prior to addition of SDS (lane 2). Arrowhead indicates minor amounts of dimers (lane 3). (F) Sedimentation analysis of IAM-alkylated and SDS-denatured (as in [E], lane 3) as compared to untreated SV40 on a linear 5%–20% sucrose gradient. (G) Wild-type and mutant SV40, where single or double cysteines had been exchanged for alanine, were produced by pNO-SV40-VP1 transfection (lanes 1–5). As control, wild-type SV40 grown by infection was used (lane 6). Preparations were alkylated (IAM), subjected to nonreducing SDS-PAGE, and immunoblotted against VP1. Arrowhead indicates monomers in the C104A mutant (lane 4). Cell 2007 131, 516-529DOI: (10.1016/j.cell.2007.09.038) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 4 ERp57-Mediated Isomerization of SV40 Disulfides Decrosslinks VP1 Molecules (A) CV-1 cells were infected with either untreated or AMS-alkylated SV40 (10 PFU/cell) for indicated times p.i. (lanes 4–9). As controls, SV40 was bound to cells at 4°C (lane 3) or infection occurred in the presence of 5 mM nocodazole (lane 2) to prevent internalization or transport from caveosomes, respectively. Cell lysates were prepared after alkylation with MMTS or NEM (data not shown). Lysates were analyzed by nonreducing SDS-PAGE and were immunoblotted against VP1. The VP1 antiserum showed much higher affinity against disulfide crosslinked molecules (especially dimers) than monomeric VP1. Hence, relative signal intensities of monomeric VP1 (boxed) were always compared to the fully reduced input (lane 9). The mean values of three independent experiments ± SD are shown. (B) PDI and ERp57 were silenced by siRNA transfection in HeLa cells prior to infection with SV40 (50 PFU/cell). The proteins of infected cells were alkylated with 5 mM MMTS (10 hr p.i.). Cell lysates were analyzed by nonreducing SDS-PAGE and immunoblotted against VP1. Quantification as in (A). (C) HeLa cells silenced for ERp57 were infected with mutant and wild-type SV40 (1 PFU/cell). (D) CV-1 cells were infected with mutant and wild-type SV40 (1 PFU/cell) in the presence or absence of DTT. The data represent the average ± SD of three independent experiments. Cell 2007 131, 516-529DOI: (10.1016/j.cell.2007.09.038) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 5 ERp57 Isomerizes SV40 Disulfide Bonds In Vitro (A) SV40 was incubated for 1 hr (37°C) in glutathione redox buffer in the presence or absence of 5 mM EGTA. The molecular ratios of reduced versus oxidized glutathione (GSH:GSSG) mimicked reducing cytosolic (100:1, lanes 4 and 5) or oxidizing ER conditions (1:1, lane 6). After 5 mM IAM alkylation, nonreducing SDS-PAGE, and immunoblotting against VP1, the amount of monomeric VP1 was determined as compared to the DTT reduced input. Mean values of relative signal intensities ± SD are shown. (B) SV40 was incubated for 1 hr (37°C) in cytosolic extracts from HeLa cells. Analysis as in (A). (C) SDS-PAGE and Coomassie staining of purified ERp57 or PDI. (D) 50 nM SV40 were incubated for 1 hr (37°C) in ER redox buffer in the presence or absence of 5 mM EGTA with purified ERp57 in the stoichiometries indicated. As controls, alkylated SV40 or alkylated ERp57 were used. Analysis as in (A). (E) As in (D) using PDI instead of ERp57. (F) Comparison of monomeric VP1 released during infection or in vitro. SV40 was treated for 1 hr (37°C) with 5 mM DTT (lane 2), ERp57 (as in [D], lane 3), PDI (as in [F], lane 5), or both thiol-disulfide oxidoreductases in equal amounts (lane 4) in vitro. Alternatively, CV-1 cells were infected for 10 hr p.i. (lane 1). Subsequently, in vitro samples or cell lysates were alkylated (5 mM MMTS), submitted to nonreducing SDS-PAGE, and immunoblotted against VP1. Cell 2007 131, 516-529DOI: (10.1016/j.cell.2007.09.038) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 6 In Vitro Disassembly of SV40 Representative examples of three independent experiments are shown ([A–E] and [G]). (A) Sucrose sedimentation analysis on a linear 5%–20% sucrose gradient of untreated, 5 mM DTT, 5 mM EGTA, or DTT/EGTA (5 mM/5 mM)-treated SV40. Fractions were immunoblotted against VP1. (B) SV40 (a) was incubated with DTT (b), EGTA (c), or DTT/EGTA (d and e) as in (A), and analyzed by negative EM. Scale bars represent 100 nM. (C) Sedimentation as in (A) after DTT/EGTA incubation of SV40. To determine the viral DNA, samples were phenol/chloroform extracted, and DNA was EtOH precipitated and quantified. (D) As in (A). Fractions immunoblotted against VP1 and VP2/VP3. (E) As in (A). Instead of infectious SV40, so-called empty particles lacking the minichromosome were used. (F) Surface rendering of the three-dimensional structure of SV40 from cryo-electron tomography after icosahedral symmetrization without (blue) or with (yellow) preincubation with DTT/EGTA. Left structure pair shows the typical orientation of the capsomers, the right structure pair is rotated horizontally to allow the view onto a vertex, revealing the missing vertex in the DTT/EGTA-treated SV40. Control virus represents average of multiple viruses; while due to the overall heterogeneity in virus diameter in the DTT/EGTA-treated population, the structure shown is from one capsid to allow a clearer view for the hexameric capsomers. The missing vertex density was, despite the heterogeneity in this preparation, the striking feature of the structure averaged from all reconstructed DTT/EGTA-treated capsids. (G) Sedimentation of SV40 after incubation with ERp57 or PDI, and EGTA addition (as in Figures 5D and 5E, lane 9) on a linear 5%–20% sucrose gradient. Fractions were immunoblotted against VP1. EGTA addition was essential for pentamer release. Cell 2007 131, 516-529DOI: (10.1016/j.cell.2007.09.038) Copyright © 2007 Elsevier Inc. Terms and Conditions

Figure 7 Interference with ER to Cytosole Retrotranslocation Coincides with Pertubation of SV40 Infection (A) CV-1 cells were infected with SV40 (wild-type and cysteine mutants) in the presence or absence of the proteasome inhibitor MG-132 (20 μM). The data represent the average ± SD of three independent experiments. (B) HeLa cells that were silenced with siRNAs directed against Derlin-1, PDI, or Luciferase were infected with SV40 (wild-type and cysteine mutants). The data represent the average ± SD of three independent experiments. (C) HeLa cells were treated with MG-132 for 16 hr. Cell lysates were subjected to SDS-PAGE and immunoblotted against ubiquitin. Shown are the polyubiquitinated proteins (poly-Ub). Poly-Ub levels as compared to MG-132-treated cells were depicted as mean ± SD. (D) Poly-Ub levels under siRNA-silencing conditions: HeLa cells were silenced for Derlin-1, Sel1L, PDI, ERp57, or ERp72, and all cells were treated for16 hr with MG-132 prior to cell lysis. Poly-UB levels as compared to control cells (Luciferase) were depicted as mean ± SD. Cell 2007 131, 516-529DOI: (10.1016/j.cell.2007.09.038) Copyright © 2007 Elsevier Inc. Terms and Conditions